DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for apolipoprotein c-III deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleApolipoprotein c-III deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for apolipoprotein c-iii deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 1987 study measured apolipoprotein C-III levels in 24 men and 21 women with normal serum and found no statistically significant difference between sexes. In both sexes, apoC-III concentration correlated positively with serum triglyceride levels. In patients with hyperlipoproteinemia, apoC-III levels were increased. The human APOC3 wild-type allele, located at 11q23.3 and approximately 3 kb in length, encodes the apolipoprotein C-III protein, which plays a role in the transport and half-life of very low density lipoproteins and chylomicrons. Mutation of the gene is associated with hyperalphalipoproteinemia 2, and fusion with the neighbouring APOA1 gene is associated with combined apoA-I and apoC-III deficiency.
A 2017 review summarised that mutations in the apolipoprotein C3 gene can render individuals susceptible or resistant to developing hyperlipidaemia and atherosclerosis. The review noted that data from this work led to the development of volanesorsen, an agent that blocks the function of the mRNA of apolipoprotein C3. Volanesorsen successfully treated severe hypertriglyceridaemia in phase 3 trials conducted by Ionis Pharmaceuticals.
No abstract in this set reports any clinical trial of volanesorsen in patients with apolipoprotein C-III deficiency itself, nor any attempt to treat the deficiency by restoring apoC-III function. The phase 3 data for volanesorsen concern severe hypertriglyceridaemia, not the deficiency state. What is missing is any trial design that directly addresses apolipoprotein C-III deficiency as a target condition, funding for such a trial, and patient stratification by the specific APOC3 mutation or fusion genotype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Lipidology · 2017 · 7 citations
Clarifying complex inheritance: apolipoprotein C3 and atherosclerosis
AbstractPURPOSE OF REVIEW: To describe some steps in the progress in the molecular biology of a peptide, apolipoprotein C3; its gene mutations that render individuals susceptible or resistant to developing hyperlipidaemia and atherosclerosis. RECENT FINDINGS: Data that lead to the development of a new therapeutic agent volanesorsen. SUMMARY: The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).
Annals of Clinical Biochemistry International Journal of Laboratory Medicine · 1987 · 4 citations
Quantitation of Apolipoprotein C-III in Normal and in Hyperlipaemic Serum Samples by Enzyme-Linked Immunosorbent Assay
AbstractA specific and sensitive Sandwich enzyme-linked immunosorbent assay (ELISA) for the quantitative determination of apolipoprotein C-III, a major apolipoprotein of human very low density lipoproteins is described. The assay is non-competitive and it uses the same affinity isolated sheep antibody both for coating the wells and as conjugate with alkaline phosphatase. Total serum apo C-III was determined in a normal population of 24 men and 21 women. The difference was not statistically significant. In both sexes apo C-III concentration correlated positively with the serum triglyceride levels. In patients with hyperlipoproteinemia, apo C-III levels were increased.
AbstractHuman APOC3 wild-type allele is located in the vicinity of 11q23.3 and is approximately 3 kb in length.T his allele, which encodes apolipoprotein C-III protein, plays a role in the transport and half-life of very low density lipoproteins and chylomicrons.Mutation of the gene is associated with hyperalphalipoproteinemia 2. Fusion of this gene with the 3' end of the neighboring APOA1 gene is associated with combined apoA-I and apoC-III deficiency.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
